The animal experiments in the present study suggest that intranas

The animal experiments in the present study suggest that intranasal immunization of KSHV induced similar immune responses to intraperitoneal immunization selleck chemicals in the production of serum IgA and saliva IgA (Fig. 2B and D). IgA level in NW of intranasally immunized mice is higher than those of intraperitoneally immunized mice (Fig. 2C). Considering that KSHV infects humans through the mucosae in the oral Libraries cavity or rectum, vaccination to the mucosae seems effectively to induce cellular and humoral immunity in human. Although it is unknown if intranasal immunization would induce similar immunity to a route using the rectum or oral cavity, the nasal or oral cavity is a promising

candidate as a route of KSHV vaccination. Immunogens BKM120 solubility dmso of KSHV are important for development of KSHV vaccine. In this study, we identified the KSHV-encoded proteins, K8.1 and ORF59, as immunogens to which mouse serum reacted (Fig. 4A). K8.1 protein, a glycoprotein composing of virion membrane, was contained by virion, while ORF59 protein, a processivity factor for viral DNA polymerase, is not detected in KSHV virions [35]. Recognition of the serum to ORF59 protein suggests a possibility that KSHV entered in mouse cells and expressed the protein for a short period. In this study, several mice immunized with KSHV

were autopsied, and all organs were investigated histopathologically. However, there was no specific disease to KSHV like KS or lymphoma, and immunohistochemistry for LANA-1 or ORF59 did not detect any positive signal in any organ, suggesting that ORF59 protein expression occurred for a very short period or at a very low rate in mice. In any case, serum from mice immunized with the K8.1 protein, but not ORF59 protein, showed some effects for prevention of KSHV infection in vitro ( Fig. 6). It is already shown that K8.1 protein interacts with cellular heparin sulfate, suggesting that K8.1 protein

MTMR9 plays an important role in the attachment of KSHV to cell surfaces [36]. Like the serum from KSHV-immunized mice, the serum from K8.1-immunized mice reduced the number of KSHV+ 293 cells partially, but not completely. The GST-fusion system cannot produce glycosylation modification, which may be one of the reasons why the serum protected 293 cells from KSHV infection partially. In addition, some previous studies demonstrated that one or a few proteins encoded by KSHV are not sufficient to detect serum antibodies to KSHV in humans, implying that single or a few recombinant viral proteins may not be sufficient for vaccine [4] and [34]. Although it is possible that some KSHV-encoded proteins may become vaccine targets [37] and [38], our data suggest that K8.1 may be one of suitable vaccine targets. The selection of adjuvant is another issue for development of KSHV vaccine. Although poly(I:C) worked well in this study, the adjuvant should be selected considering the route of vaccination, volume of vaccine, and characterization of vaccine product.

Leave a Reply

Your email address will not be published. Required fields are marked *


You may use these HTML tags and attributes: <a href="" title=""> <abbr title=""> <acronym title=""> <b> <blockquote cite=""> <cite> <code> <del datetime=""> <em> <i> <q cite=""> <strike> <strong>